Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth.
An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Did Harmony Biosciences Holdings, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- HRMY
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Levi & Korsinsky Reminds Shareholders of an Investigation into Harmony Biosciences Holdings, Inc. (HRMY) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
HRMY vs. REGN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks is more attractive to value investors?
Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
